|
|
|
|
|
02.06.25 - 23:42
|
XFRA: DIVIDEND/INTEREST INFORMATION - 04.06.2025 - EQUBF_01 (XETRA)
|
|
|
Das Instrument 8JM FR0004186856 VETOQUINOL INH. EO 2,50 EQUITY wird cum Dividende/Zinsen gehandelt am 03.06.2025 und ex Dividende/Zinsen am 04.06.2025
The instrument 8JM FR0004186856 VETOQUINOL INH. EO 2,50 EQUITY has its pre-dividend/interest day on 03.06.2025 and its ex-dividend/interest day on 04.06.2025...
|
|
|
25.04.25 - 10:03
|
Vetoquinol Group: Sales for 1st Quarter 2025 (Business Wire)
|
|
|
Essential products sales: €85m (+1.8% at constant exchange rates and on a reported basis)
LURE, France--(BUSINESS WIRE)--Regulatory News:
Vetoquinol Group (Paris:VETO):
First-quarter sales of Essential products totaled 85 million euros, up+ 1.8% at constant exchange rates.
Sales of Essential products in Q1 2025 continued to grow in all territories outside the USA. Europe, the Group's largest market, grew by over 3%, the Americas (excluding the USA) by over 4%, and Asia-Pacific/Rest of the World posted strong growth of close to 25% at constant exchange rates. The United States was down sharply, penalized by a wait-and-see market and the slower-than-expected return to normal sales of the range unavailable in 2024.
At the same time, the Group is pursuing its rationalization program for non-critical complementary ranges, which automatically led to a drop in sales of these products of around €2.0 million in Q1
In Q1 2025, sales of Essential products represented 65% of Vetoquinol's sales.
Overall, on a re...
|
|
|
20.03.25 - 17:51
|
Vetoquinol: Annual Results 2024 (Business Wire)
|
|
|
Annual sales: €539m (+2.2% at constant exchange rates)
Essential products sales: €328m (+4.6% at constant exchange rates)
Net result, Group share: €59m (10.9% of sales)
EBITDA: €104m (19.3% of sales)
Cash flow generation: €86m
LURE, France--(BUSINESS WIRE)--Regulatory News:
Matthieu Frechin, Chairman and CEO of Vetoquinol (Paris:VETO), commented: "In 2024, we delivered a solid financial year, combining growth in almost all our reference markets, high profitability and sustained cash generation. We have achieved this performance while absorbing the sometimes significant uncertainties, such as in the United States this year, as well as the cost of transforming the Group. This is due to the strength of our model built around Essentials, which have achieved an annual average growth above 8% since 2014, and to our reactive management, which enables us to adapt quickly to changing economic conditions.
We will therefore actively pursue the implementation of this strategy in 2025, while paying part...
|
|
|
30.01.25 - 17:48
|
Vetoquinol: Annual Sales 2024 (Business Wire)
|
|
|
Annual sales: €539 million (up 2.2% at constant exchange rates and up 1.9%. on a reported basis)
Annual sales of Essential products: €328 million (up 4.6% at constant exchange rates and on a reported basis)LURE, France--(BUSINESS WIRE)--Regulatory News:
Matthieu Frechin, Chairman and CEO of Vetoquinol (Paris:VETO), commented: "All our activities and territories are growing, with the exception of the United States for one-off reasons. We are on track to deliver long-term profitable growth. We owe this to our focus strategy and the power of our "Essentials" model, which has delivered average annual growth of over 8% for the past 10 years. We will continue to pursue this strategy in 2025."
Vetoquinol's sales for FY 2024 came to €539 million, up 1.9 % on a reported basis and 2.2% at constant exchange rates.
Exchange rates had a negative impact of -€1.9 million.
Sales for the 4th quarter totaled €141 million, up 2.8% on a reported basis and up 3.4% at constant exchange rates, dri...
|
|
|
15.01.25 - 17:51
|
Vetoquinol: 2025 Calendar of Financial Communication (Business Wire)
|
|
|
LURE, France--(BUSINESS WIRE)--Regulatory News:
Vetoquinol (Paris:VETO) published its calendar of financial communication for 2025.
January 30, 2025
2024 Annual Sales (after market)
March 20, 2025
2024 Annual results (confcall after market)
April 24, 2025
2025 First quarter sales (after market)
May 22, 2025
Annual shareholders' meeting
June 6, 2025
Dividend payment
September 11, 2025
2025 First semester results (confcall after market)
October 28, 2025
2025 Third quarter sales (after market)
Next update: Annual Sales 2024, January 30th, 2025 after market close
ABOUT VETOQUINOL
Vetoquinol is a leading international player in animal health, with operations in Europe, the Americas and Asia/Pacific.
Independent and a pure player, Vetoquinol innovates, develops and markets veterinary medicines and non-medicated products for farm animals (cattle, pigs) and pets (dogs, cats).
Since its creation in 1933, Vetoquinol has combined innovation and geographic diversification. The strengthening of the product portfolio ...
|
|
|
|
|
|
|
|
|
|
|
02.06.24 - 21:49
|
XFRA : DIVIDEND/INTEREST INFORMATION - 04.06.2024 - FR0004186856 (XETRA)
|
|
|
Das Instrument 8JM FR0004186856 VETOQUINOL INH. EO 2,50 EQUITY wird cum Dividende/Zinsen gehandelt am 03.06.2024 und ex Dividende/Zinsen am 04.06.2024
The instrument 8JM FR0004186856 VETOQUINOL INH. EO 2,50 EQUITY has its pre-dividend/interest day on 03.06.2024 and its ex-dividend/interest day on 04.06.2024...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
